View Agent
| Agent Info | |
| Agent: | cabozantinib |
| Synonyms: | XL184 |
| Drug Status For Certain Diseases: | Metastatic medullary thyroid cancer(approved) |
| Classification: | an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2 |
| Target: | Hepatocyte growth factor receptor Vascular endothelial growth factor receptor 2 |
| KEGG Pathway: | VEGF signaling pathway Cytokine-cytokine receptor interaction PI3K-Akt signaling pathway Pathways in cancer Adherens junction Transcriptional misregulation in cancer Epithelial cell signaling in Helicobacter pylori infection Bacterial invasion of epithelial cells Axon guidance Endocytosis Ras signaling pathway Central carbon metabolism in cancer MicroRNAs in cancer Melanoma Proteoglycans in cancer Rap1 signaling pathway Focal adhesion Renal cell carcinoma |
| Wiki Pathway: | miR-targeted genes in muscle cell - TarBase Focal Adhesion Signaling Pathways in Glioblastoma Semaphorin interactions Signaling by VEGF TGF beta Signaling Pathway Cardiac Progenitor Differentiation miR-targeted genes in lymphocytes - TarBase Extracellular vesicle-mediated signaling in recipient cells Angiogenesis miR-targeted genes in squamous cell - TarBase miR-targeted genes in epithelium - TarBase Nifedipine Activity Signaling of Hepatocyte Growth Factor Receptor |